Mark J. Ratain to Biological Availability
This is a "connection" page, showing publications Mark J. Ratain has written about Biological Availability.
Connection Strength
0.465
-
Food Effect Studies for Oncology Drug Products. Clin Pharmacol Ther. 2017 May; 101(5):606-612.
Score: 0.148
-
Importance of food effects for oral oncology drugs. Clin Adv Hematol Oncol. 2012 Jun; 10(6):397-8.
Score: 0.106
-
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010 Sep 01; 16(17):4446-51.
Score: 0.094
-
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
Score: 0.053
-
Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998 Jul; 16(7):2557-67.
Score: 0.040
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.016
-
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin Cancer Res. 1995 Oct; 1(10):1133-8.
Score: 0.008